The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...

Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu ...

President Trump’s chief cost-cutter cheered an effort to persuade federal workers to quit — in a fashion that closely ...

Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...

Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people familiar with the matter.

(NYSE:PFE) has temporarily avoided a standoff with activist investor Starboard Value LP. According to Bloomberg sources, ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Starboard last year took a $1 billion stake in Pfizer, looking to turn the pharma around after alleged severe shortcomings by ...

Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S.

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Chief Executive Officer Albert Bourla said at the JPMorgan Healthcare Conference on Monday. Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company ...